Research focuses on eight countries where the correct antibiotics are not available

Research from the Global Antibiotic R&D Partnership for Nonprofit Health Organization shows that there are a large number of multidrug-resistant infections in low- and middle-income countries, including India, due to a large gap in visits. |Photo source: Reuters

In India, only 7.8% of patients with drug-resistant infections received appropriate antibiotics, a study published in eight countries Lancet infectious disease The diary has been revealed. In addition to increasing health care costs and extending hospitalization, the lack of access to appropriate treatment for such severe infections can increase morbidity and mortality.

Research conducted by the nonprofit Health Organization’s Global Partnership on Antibiotics Research and Development (GARDP) shows that a wide range of drug-resistant infections in low- and middle-income countries, including India, are properly treated due to the large range of visits.

The study examines which antibiotics can be used to treat nearly 1.5 million cases of anti-carbapenem (CRGN) infections in eight geographically diverse and populated LMICs – Bangladesh, Brazil, India, India, Kenya, Mexico, Mexico, Pakistan and South Africa. India’s 7.8% measure is the average measure in all eight countries at 6.9%.

This study was conducted to establish barriers in the treatment pathway, from initial introductions in healthcare facilities to laboratory diagnostic testing to antibiotic acquisition.

Two key parameters

The researchers defined and estimated two key parameters – the total number of treatment or resistant bacterial infections; the number of individuals potentially initiated appropriate treatment, specifically targeting CRGN infections. The researchers used it The LancetThe 2019 Global Antibacterial Resistance Burden (GRAM) study and IQVIA data reached these figures.

“We are looking at three aspects,” explains Jennifer Cohn, Global Visiting Director and Senior Research Author, GARDP. “These are: assessing access to the antibiotic gap; creating better data that would be necessary to better define cascading care; and looking at powerful programs or innovations that enable better antibiotic management in countries.” Although the study focused only on eight countries, including India, she said there is good reason to believe that the findings of this study also apply to other LMICs.

“We all know that in countries like India, high-end antibiotics are widely used and abused, which contributes a lot to the fight against these life-saving drugs. However, this article reminds us of an equally shocking question – the lack of opportunities for these same antibiotics,” said Abdul Ghafur, an expert and founder of Infectious Disecees Specialises, AMR statement.

“In 2019, India suffered from nearly 1 million carbapenem-induced infections, but fewer than 10,000 patients were treated appropriately. The model shows that there were about 3.5 million deaths due to these infections. So we are trapped in a paradox – inadequate use of the paradigm on one end and inadequate scope on the other.”

Dr. Ghafur further advises: “To resolve this double crisis, we must act on both aspects: to preserve existing antibiotics through responsible use and ensure access with those who really need them.” In the paper written by Anant Mishra et al, these recommendations are intended to determine not only the regulatory barriers that can control antibiotic use, but also ensure access gaps are bridged by countries and agencies. They also call for more research to better understand barriers to accessing care, diagnosis, and proper treatment.